
Maria G Masucci

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5048571/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Epstein-Barr virus deubiquitinase BPLF1 targets SQSTM1/p62 to inhibit selective autophagy. Autophagy, 2021, 17, 3461-3474.	9.1	22
2	Inhibition of selective autophagy by members of the herpesvirus ubiquitin-deconjugase family. Biochemical Journal, 2021, 478, 2297-2308.	3.7	3
3	The Epstein-Barr virus deubiquitinating enzyme BPLF1 regulates the activity of topoisomerase II during productive infection. PLoS Pathogens, 2021, 17, e1009954.	4.7	10
4	Herpesvirus ubiquitin deconjugases. Seminars in Cell and Developmental Biology, 2021, , .	5.0	2
5	The Epstein–Barr virus nuclear antigen-1 upregulates the cellular antioxidant defense to enable B-cell growth transformation and immortalization. Oncogene, 2020, 39, 603-616.	5.9	16
6	Interaction With 14-3-3 Correlates With Inactivation of the RIG-I Signalosome by Herpesvirus Ubiquitin Deconjugases. Frontiers in Immunology, 2020, 11, 437.	4.8	20
7	A bacterial genotoxin causes virus reactivation and genomic instability in Epstein–Barr virus infected epithelial cells pointing to a role of coâ€infection in viral oncogenesis. International Journal of Cancer, 2019, 144, 98-109.	5.1	10
8	Infection with genotoxinâ€producing <i>Salmonella enterica</i> synergises with loss of the tumour suppressor <i>APC</i> in promoting genomic instability via the PI3K pathway in colonic epithelial cells. Cellular Microbiology, 2019, 21, e13099.	2.1	26
9	14-3-3 scaffold proteins mediate the inactivation of trim25 and inhibition of the type I interferon response by herpesvirus deconjugases. PLoS Pathogens, 2019, 15, e1008146.	4.7	44
10	Herpesvirus deconjugases inhibit the IFN response by promoting TRIM25 autoubiquitination and functional inactivation of the RIG-I signalosome. PLoS Pathogens, 2018, 14, e1006852.	4.7	56
11	A novel mechanism for regulation of the type I IFN response by herpesvirus deconjugases. Microbial Cell, 2018, 5, 259-261.	3.2	2
12	Regulation of Telomere Homeostasis during Epstein-Barr virus Infection and Immortalization. Viruses, 2017, 9, 217.	3.3	18
13	The Epstein-Barr virus miR-BHRF1-1 targets RNF4 during productive infection to promote the accumulation of SUMO conjugates and the release of infectious virus. PLoS Pathogens, 2017, 13, e1006338.	4.7	18
14	Oxidative stress enables Epstein–Barr virus-induced B-cell transformation by posttranscriptional regulation of viral and cellular growth-promoting factors. Oncogene, 2016, 35, 3807-3816.	5.9	39
15	Epstein–Barr virus encoded micro <scp>RNA</scp> s target <scp>SUMO</scp> â€regulated cellular functions. FEBS Journal, 2014, 281, 4935-4950.	4.7	15
16	Emerging topics in human tumor virology. Seminars in Cancer Biology, 2014, 26, 1-3.	9.6	0
17	Tumor viruses and replicative immortality – Avoiding the telomere hurdle. Seminars in Cancer Biology, 2014, 26, 43-51.	9.6	11
18	An N-terminal SIAH-interacting motif regulates the stability of the ubiquitin specific protease (USP)-19. Biochemical and Biophysical Research Communications, 2013, 433, 390-395	2.1	12

#	Article	IF	CITATIONS
19	The Gly–Ala repeat modulates the interaction of Epstein–Barr virus nuclear antigen-1 with cellular chromatin. Biochemical and Biophysical Research Communications, 2013, 431, 706-711.	2.1	4
20	Telomere dysfunction and activation of alternative lengthening of telomeres in B-lymphocytes infected by Epstein–Barr virus. Oncogene, 2013, 32, 5522-5530.	5.9	47
21	Chronic exposure to the cytolethal distending toxins of Gram-negative bacteria promotes genomic instability and altered DNA damage response. Cellular Microbiology, 2013, 15, 98-113.	2.1	97
22	Caspase-1 Promotes Epstein-Barr Virus Replication by Targeting the Large Tegument Protein Deneddylase to the Nucleus of Productively Infected Cells. PLoS Pathogens, 2013, 9, e1003664.	4.7	40
23	The Epstein–Barr virus nuclear antigen-1 reprograms transcription by mimicry of high mobility group A proteins. Nucleic Acids Research, 2013, 41, 2950-2962.	14.5	40
24	Interaction of Gamma-Herpesvirus Genome Maintenance Proteins with Cellular Chromatin. PLoS ONE, 2013, 8, e62783.	2.5	4
25	Herpes virus deneddylases interrupt the cullin-RING ligase neddylation cycle by inhibiting the binding of CAND1. Journal of Molecular Cell Biology, 2012, 4, 242-251.	3.3	27
26	Ubiquitin Câ€ŧerminal hydrolase‣1 interacts with adhesion complexes and promotes cell migration, survival, and anchorage independent growth. FASEB Journal, 2012, 26, 5060-5070.	0.5	20
27	The ubiquitin specific protease-4 (USP4) interacts with the S9/Rpn6 subunit of the proteasome. Biochemical and Biophysical Research Communications, 2012, 427, 490-496.	2.1	9
28	Remodeling of the epitope repertoire of a candidate idiotype vaccine by targeting to lysosomal degradation in dendritic cells. Cancer Immunology, Immunotherapy, 2012, 61, 881-892.	4.2	5
29	Helicobacter pylori affects the cellular deubiquitinase USP7 and ubiquitin-regulated components TRAF6 and the tumour suppressor p53. International Journal of Medical Microbiology, 2011, 301, 213-224.	3.6	26
30	Thioredoxin 80-Activated-Monocytes (TAMs) Inhibit the Replication of Intracellular Pathogens. PLoS ONE, 2011, 6, e16960.	2.5	18
31	The Epstein–Barr virus nuclear antigen-1 promotes telomere dysfunction via induction of oxidative stress. Leukemia, 2011, 25, 1017-1025.	7.2	73
32	High Avidity Binding to DNA Protects Ubiquitylated Substrates from Proteasomal Degradation. Journal of Biological Chemistry, 2011, 286, 19565-19575.	3.4	12
33	Bacterial genotoxin triggers FEN1-dependent RhoA activation, cytoskeleton remodeling and cell survival. Journal of Cell Science, 2011, 124, 2735-2742.	2.0	35
34	Characterization of an human leucocyte antigen A2â€restricted Epstein–Barr virus nuclear antigenâ€1â€derived cytotoxic Tâ€lymphocyte epitope. Immunology, 2010, 129, 386-395.	4.4	9
35	A deneddylase encoded by Epstein–Barr virus promotes viral DNA replication by regulating the activity of cullin-RING ligases. Nature Cell Biology, 2010, 12, 351-361.	10.3	103
36	The ubiquitin C-terminal hydrolase UCH-L1 promotes bacterial invasion by altering the dynamics of the actin cytoskeleton. Cellular Microbiology, 2010, 12, 1622-1633.	2.1	24

#	Article	IF	CITATIONS
37	The Translation Initiation Factor 3f (eIF3f) Exhibits a Deubiquitinase Activity Regulating Notch Activation. PLoS Biology, 2010, 8, e1000545.	5.6	74
38	Transcription Profiling of Epstein-Barr Virus Nuclear Antigen (EBNA)-1 Expressing Cells Suggests Targeting of Chromatin Remodeling Complexes. PLoS ONE, 2010, 5, e12052.	2.5	23
39	The Epstein-Barr virus nuclear antigen-1 promotes genomic instability via induction of reactive oxygen species. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 2313-2318.	7.1	200
40	EBV and genomic instability—A new look at the role of the virus in the pathogenesis of Burkitt's lymphoma. Seminars in Cancer Biology, 2009, 19, 394-400.	9.6	44
41	The ubiquitin Câ€terminal hydrolase UCHâ€L1 regulates Bâ€cell proliferation and integrin activation. Journal of Cellular and Molecular Medicine, 2009, 13, 1666-1678.	3.6	25
42	The ubiquitin specific protease 4 (USP4) is a new player in the Wnt signalling pathway. Journal of Cellular and Molecular Medicine, 2009, 13, 1886-1895.	3.6	68
43	The ERâ€resident ubiquitinâ€specific protease 19 participates in the UPR and rescues ERAD substrates. EMBO Reports, 2009, 10, 755-761.	4.5	125
44	Three Epstein–Barr virus latency proteins independently promote genomic instability by inducing DNA damage, inhibiting DNA repair and inactivating cell cycle checkpoints. Oncogene, 2009, 28, 3997-4008.	5.9	141
45	The ubiquitin specific protease 4 (USP4) is a new player in the Wnt signalling pathway. Journal of Cellular and Molecular Medicine, 2009, 13, 1886-1895.	3.6	48
46	Inhibition of Serineâ€Peptidase Activity Enhances the Generation of a Survivinâ€Derived HLAâ€A2â€Presented CTL Epitope in Colonâ€Carcinoma Cells. Scandinavian Journal of Immunology, 2008, 68, 579-588.	2.7	8
47	Epstein-Barr Virus Encodes Three Bona Fide Ubiquitin-Specific Proteases. Journal of Virology, 2008, 82, 10477-10486.	3.4	36
48	The MAPK Signaling Cascade is a Central Hub in the Regulation of Cell Cycle, Apoptosis and Cytoskeleton Remodeling by Tripeptidyl-Peptidase II. Gene Regulation and Systems Biology, 2008, 2, GRSB.S882.	2.3	9
49	A Bacterial Cytotoxin Identifies the RhoA Exchange Factor Net1 as a Key Effector in the Response to DNA Damage. PLoS ONE, 2008, 3, e2254.	2.5	69
50	Expression of immune-related molecules in primary EBV positive chinese nasopharyngeal carcinoma: Associated with latent membrane protein 1 (LMP1) expression. Cancer Biology and Therapy, 2007, 6, 1997-2004.	3.4	32
51	Functional Inactivation of EBV-Specific T-Lymphocytes in Nasopharyngeal Carcinoma: Implications for Tumor Immunotherapy. PLoS ONE, 2007, 2, e1122.	2.5	85
52	Epstein–Barr virus promotes genomic instability in Burkitt's lymphoma. Oncogene, 2007, 26, 5115-5123.	5.9	89
53	Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine. Cancer Immunology, Immunotherapy, 2007, 56, 1597-1604.	4.2	135
54	TPPII promotes genetic instability by allowing the escape from apoptosis of cells with activated mitotic checkpoints. Biochemical and Biophysical Research Communications, 2006, 346, 415-425.	2.1	23

#	Article	IF	CITATIONS
55	Non-infectious fluorimetric assay for phenotyping of drug-resistant HIV proteinase mutants. Journal of Clinical Virology, 2006, 36, 50-59.	3.1	12
56	Is the Activity of Partially Agonistic MHC:Peptide Ligands Dependent on the Quality of Immunological Help?. Scandinavian Journal of Immunology, 2006, 64, 581-587.	2.7	8
57	The ubiquitin-specific protease USP25 interacts with three sarcomeric proteins. Cellular and Molecular Life Sciences, 2006, 63, 723-734.	5.4	44
58	Activity profiling of deubiquitinating enzymes in cervical carcinoma biopsies and cell lines. Molecular Carcinogenesis, 2006, 45, 260-269.	2.7	103
59	GFP reporter mouse models of UPS proteolytic function. FASEB Journal, 2006, 20, 1027-1028.	0.5	3
60	Help signals provided by lymphokines modulate the activation and apoptotic programs induced by partially agonistic peptides in specific cytotoxic T lymphocytes. European Journal of Immunology, 2005, 35, 2929-2939.	2.9	7
61	Hepatitis C Virus Core Protein Induces an Anergic State Characterized by Decreased Interleukin-2 Production and Perturbation of Mitogen-Activated Protein Kinase Responses. Journal of Virology, 2005, 79, 2230-2239.	3.4	29
62	Endoplasmic reticulum stress compromises the ubiquitin–proteasome system. Human Molecular Genetics, 2005, 14, 2787-2799.	2.9	181
63	Mitotic Infidelity and Centrosome Duplication Errors in Cells Overexpressing Tripeptidyl-Peptidase II. Cancer Research, 2005, 65, 1361-1368.	0.9	46
64	Regulation of lck degradation and refractory state in CD8+ cytotoxic T lymphocytes. Proceedings of the United States of America, 2005, 102, 9264-9269.	7.1	17
65	The UBA2 Domain Functions as an Intrinsic Stabilization Signal that Protects Rad23 from Proteasomal Degradation. Molecular Cell, 2005, 18, 225-235.	9.7	103
66	Regulation of expression of Bcl-2 protein family member Bim by T cell receptor triggering. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 3011-3016.	7.1	65
67	Activity-based ubiquitin-specific protease (USP) profiling of virus-infected and malignant human cells. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 2253-2258.	7.1	191
68	Capacity of Epstein–Barr virus to infect monocytes and inhibit their development into dendritic cells is affected by the cell type supporting virus replication. Journal of General Virology, 2004, 85, 2767-2778.	2.9	54
69	Effect of combined T- and B-cell depletion of allogeneic HLA-mismatched bone marrow graft on the magnitude and kinetics of Epstein-Barr virus load in the peripheral blood of bone marrow transplant recipients. Clinical Transplantation, 2004, 18, 518-524.	1.6	14
70	Differential Regulation of MHC Class-I-Restricted and Unrestricted Cytotoxicity by the Us3 Protein Kinase of Herpes Simplex Virus-1. Scandinavian Journal of Immunology, 2004, 60, 592-599.	2.7	9
71	Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumors. Nature Medicine, 2004, 10, 1321-1328.	30.7	746
72	Epstein–Barr virus oncogenesis and the ubiquitin–proteasome system. Oncogene, 2004, 23, 2107-2115.	5.9	49

5

#	Article	IF	CITATIONS
73	The ubiquitin/proteasome system in Epstein–Barr virus latency and associated malignancies. Seminars in Cancer Biology, 2003, 13, 69-76.	9.6	28
74	Epstein–Barr virus: Induction and control of cell transformation. Journal of Cellular Physiology, 2003, 196, 207-218.	4.1	69
75	Pharmacological Disintegration of Lipid Rafts Decreases Specific Tetramer Binding and Disrupts the CD3 Complex and CD8 Heterodimer in Human Cytotoxic T Lymphocytes. Scandinavian Journal of Immunology, 2003, 57, 99-106.	2.7	15
76	The herpes simplex virus-1 Us3 protein kinase blocks CD8T cell lysis by preventing the cleavage of Bid by granzyme B. Cell Death and Differentiation, 2003, 10, 1320-1328.	11.2	48
77	A transgenic mouse model of the ubiquitin/proteasome system. Nature Biotechnology, 2003, 21, 897-902.	17.5	214
78	Inhibition of ubiquitin/proteasome-dependent proteolysis inSaccharomyces cerevisiaeby a Gly-Ala repeat. FEBS Letters, 2003, 555, 397-404.	2.8	39
79	The Us3 protein kinase of herpes simplex virus 1 blocks apoptosis and induces phosporylation of the Bcl-2 family member Bad. Experimental Cell Research, 2003, 291, 242-250.	2.6	54
80	The Hepatitis C Virus Core Protein Modulates T Cell Responses by Inducing Spontaneous and Altering T-cell Receptor-triggered Ca2+ Oscillations. Journal of Biological Chemistry, 2003, 278, 18877-18883.	3.4	57
81	Stabilization of proteasomal substrates by viral repeats. New Comprehensive Biochemistry, 2003, 38, 535-549.	0.1	0
82	Soluble Factors Released by Virus Specific Activated Cytotoxic Tâ€lymphocytes Induce Apoptotic Death of Astroglioma Cell Lines. Brain Pathology, 2003, 13, 165-175.	4.1	4
83	Functional p53 chimeras containing the Epstein-Barr virus Gly-Ala repeat are protected from Mdm2- and HPV-E6-induced proteolysis. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 1532-1537.	7.1	42
84	Aggregate formation inhibits proteasomal degradation of polyglutamine proteins. Human Molecular Genetics, 2002, 11, 2689-2700.	2.9	252
85	MYC overexpression imposes a nonimmunogenic phenotype on Epstein-Barr virus-infected B cells. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 4550-4555.	7.1	67
86	Mutant ubiquitin found in neurodegenerative disorders is a ubiquitin fusion degradation substrate that blocks proteasomal degradation. Journal of Cell Biology, 2002, 157, 417-427.	5.2	197
87	Epstein-Barr virus inhibits the development of dendritic cells by promoting apoptosis of their monocyte precursors in the presence of granulocyte macrophage–colony-stimulating factor and interleukin-4. Blood, 2002, 99, 3725-3734.	1.4	87
88	Inhibition of ubiquitin-dependent proteolysis by a synthetic glycine-alanine repeat peptide that mimics an inhibitory viral sequence. FEBS Letters, 2002, 522, 93-98.	2.8	15
89	Stabilization signals: a novel regulatory mechanism in the ubiquitin/proteasome system. FEBS Letters, 2002, 529, 22-26.	2.8	29
90	Manipulation of immune responses by Epstein–Barr virus. Virus Research, 2002, 88, 71-86.	2.2	31

#	Article	IF	CITATIONS
91	Tetramer binding and secretion of interferon-Î ³ in response to antigenic stimulation are compatible with a range of affinities of MHC:TCR interaction and distinct programs of cytotoxic T-lymphocyte activation. Human Immunology, 2002, 63, 821-833.	2.4	6
92	Proteasome inhibitors reconstitute the presentation of cytotoxic T-cell epitopes in Epstein-Barr virus-associated tumors. International Journal of Cancer, 2002, 101, 532-538.	5.1	36
93	The Haemophilus ducreyi cytolethal distending toxin activates sensors of DNA damage and repair complexes in proliferating and non-proliferating cells. Cellular Microbiology, 2002, 4, 87-99.	2.1	105
94	Inhibition of the Ubiquitin-Proteasome System by a Viral Repetitive Sequence. , 2002, , 189-203.		0
95	cis-Inhibition of proteasomal degradation by viral repeats: impact of length and amino acid composition. FEBS Letters, 2001, 499, 137-142.	2.8	38
96	Generation of Lymphoblastoid Cell Lines (LCLs). , 2001, 174, 125-127.		22
97	c-myc overexpression activates alternative pathways for intracellular proteolysis in lymphoma cells. Nature Cell Biology, 2001, 3, 283-288.	10.3	103
98	Cell-Based Fluorescence Assay for Human Immunodeficiency Virus Type 1 Protease Activity. Antimicrobial Agents and Chemotherapy, 2001, 45, 2616-2622.	3.2	41
99	Different Programs of Activation-Induced Cell Death Are Triggered in Mature Activated CTL by Immunogenic and Partially Agonistic Peptide Ligands. Journal of Immunology, 2001, 166, 989-995.	0.8	16
100	Generation of Polyclonal EBV-Specific CTL Cultures and Clones. , 2001, 174, 203-208.		4
101	Variations in proteasome subunit composition and enzymatic activity in B-lymphoma lines and normal B cells. International Journal of Cancer, 2000, 88, 881-888.	5.1	30
102	Effect of Interleukin-7 on the In Vitro Development and Maturation of Monocyte Derived Human Dendritic Cells. Scandinavian Journal of Immunology, 2000, 51, 361-371.	2.7	36
103	Short-lived green fluorescent proteins for quantifying ubiquitin/proteasome-dependent proteolysis in living cells. Nature Biotechnology, 2000, 18, 538-543.	17.5	535
104	Reply to â€~Ubiquitin/proteasome system'. Nature Biotechnology, 2000, 18, 807-807.	17.5	2
105	Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood, 2000, 95, 807-814.	1.4	315
106	Inhibition of proteasomal degradation by the Gly-Ala repeat of Epstein-Barr virus is influenced by the length of the repeat and the strength of the degradation signal. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 8381-8385.	7.1	76
107	Supermotif peptide binding and degeneracy of MHC: peptide recognition in an EBV peptide-specific CTL response with highly restricted TCR usage. Human Immunology, 2000, 61, 972-984.	2.4	6
108	A minimal glycine-alanine repeat prevents the interaction of ubiquitinated ll̂ºBα with the proteasome: a new mechanism for selective inhibition of proteolysis. Nature Medicine, 1998, 4, 939-944.	30.7	128

#	Article	IF	CITATIONS
109	High structural side chain specificity required at the second position of immunogenic peptides to obtain stable MHC/peptide complexes. FEBS Letters, 1998, 421, 95-99.	2.8	12
110	Random coil conformation of a Gly/Ala-rich insert in lκBα excludes structural stabilization as the mechanism for protection against proteasomal degradation. FEBS Letters, 1998, 440, 365-369.	2.8	16
111	Avoiding Immunity and Apoptosis: Manipulation of the Host Environment by Herpes Simplex Virus and Epstein-Barr Virus. Seminars in Virology, 1998, 8, 361-368.	3.9	2
112	Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 12616-12621.	7.1	500
113	Epitope-dependent Selection of Highly Restricted or Diverse T Cell Receptor Repertoires in Response to Persistent Infection by Epstein-Barr Virus. Journal of Experimental Medicine, 1997, 186, 83-89.	8.5	91
114	HLA-A11-mediated protection from NK cell-mediated lysis. Human Immunology, 1996, 49, 1-12.	2.4	13
115	Strategies of immunoescape in Epstein-Barr virus persistence and pathogenesis. Seminars in Virology, 1996, 7, 75-82.	3.9	9
116	Defective presentation of MHC class I-restricted cytotoxic T-cell epitopes in Burkitt's lymphoma cells. , 1996, 68, 251-258.		42
117	The life span of major histocompatibility complex-peptide complexes influences the efficiency of presentation and immunogenicity of two class I-restricted cytotoxic T lymphocyte epitopes in the Epstein-Barr virus nuclear antigen 4 Journal of Experimental Medicine, 1996, 183, 915-926.	8.5	124
118	Solvent exposed side chains of peptides bound to HLA A*1101 have similar effects on the reactivity of alloantibodies and specific TCR. International Immunology, 1996, 8, 927-938.	4.0	19
119	Virus induced cancer: The lesson of Epstein—Barr virus. , 1996, , 161-175.		0
120	Mechanisms of allele-selective down-regulation of HLA class I in Burkitt's lymphoma. International Journal of Cancer, 1995, 62, 90-96.	5.1	30
121	Inhibition of antigen processing by the internal repeat region of the Epstein–Barr virus nuclear antigen-1. Nature, 1995, 375, 685-688.	27.8	799
122	Effect of Anchor Residue Modifications on the Stability of HLA-A11/Peptide Complexes. Biochemical and Biophysical Research Communications, 1995, 206, 8-14.	2.1	17
123	Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expression Journal of Experimental Medicine, 1994, 180, 2371-2376.	8.5	299
124	T cell responses and virus evolution: loss of HLA A11-restricted CTL epitopes in Epstein-Barr virus isolates from highly A11-positive populations by selective mutation of anchor residues Journal of Experimental Medicine, 1994, 179, 1297-1305.	8.5	171
125	The epstein-barr virus latent membrane protein-1 (LMP1) induces interleukin-10 production in burkitt lymphoma lines. International Journal of Cancer, 1994, 57, 240-244.	5.1	132
126	Epstein-Barr virus: adaptation to a life within the immune system. Trends in Microbiology, 1994, 2, 125-130.	7.7	120

#	Article	IF	CITATIONS
127	Epstein-Barr virus (EBV)-encoded membrane protein LMP1 from a nasopharyngeal carcinoma is non-immunogenic in a murine model system, in contrast to a B cell-derived homologue. European Journal of Cancer, 1994, 30, 84-88.	2.8	93
128	Viral immunopathology of human tumors. Current Opinion in Immunology, 1993, 5, 693-700.	5.5	28
129	Viral and Cellular Factors Influence the Activity of the Epstein-Barr Virus BCR2 and BWR1 Promoters in Cells of Different Phenotype. Virology, 1993, 193, 774-785.	2.4	29
130	Selective induction of allostimulatory capacity after 5-azaC treatment of EBV carrying but not EBV negative burkitt lymphoma cell lines. Molecular Immunology, 1993, 30, 441-450.	2.2	9
131	Transformation-Associated Epstein-Barr Virus Antigens as Targets for Immune Attack. Annals of the New York Academy of Sciences, 1993, 690, 86-100.	3.8	9
132	An HLA-A11-specific motif in nonamer peptides derived from viral and cellular proteins Proceedings of the United States of America, 1993, 90, 2217-2221.	7.1	89
133	HLA-A11 epitope loss isolates of Epstein-Barr virus from a highly A11+ population. Science, 1993, 260, 98-100.	12.6	272
134	Overâ€expression of câ€ <i>myc</i> increases the sensitivity of epsteinâ€barr virus immortalized lymphoblastoid cells to nonâ€MHCâ€restricted cytotoxicity. International Journal of Cancer, 1993, 53, 1008-1012.	5.1	4
135	Multiple HLA A11-restricted cytotoxic T-lymphocyte epitopes of different immunogenicities in the Epstein-Barr virus-encoded nuclear antigen 4. Journal of Virology, 1993, 67, 1572-1578.	3.4	164
136	Immune escape by Epstein-Barr virus (EBV) carrying Burkitt's lymphoma: in vitro reconstitution of sensitivity to EBV-specific cytotoxic T cells. International Immunology, 1992, 4, 1283-1292.	4.0	26
137	Recognition of the Epstein-Barr virus-encoded nuclear antigens EBNA-4 and EBNA-6 by HLA-A11-restricted cytotoxic T lymphocytes: implications for down-regulation of HLA-A11 in Burkitt lymphoma Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 5862-5866.	7.1	106
138	Expression of the epstein-barr virus (EBV)-encoded membrane protein LMP1 impairs theln vitro growth, clonability and tumorigenicity of an EBV-negative burkitt lymphoma line. International Journal of Cancer, 1992, 51, 949-955.	5.1	28
139	Suppression of basal, PMA-and IFN-α-, but not IFN-γ-induced expression of HLA class I in v-myc-transformed U-937 monoblasts. International Journal of Cancer, 1992, 52, 759-765.	5.1	2
140	Methylation of discrete sites within the enhancer region regulates the activity of the Epstein-Barr virus BamHI W promoter in Burkitt lymphoma lines. Journal of Virology, 1992, 66, 62-69.	3.4	63
141	Stimulation with allogeneic epstein-barr virus-transformed lymphoblastoid cell lines generates HLA class I-specific CTLs with different target cell avidity. Cellular Immunology, 1991, 137, 501-513.	3.0	4
142	aberrant expression of HLA Class-I antigens in burkitt lymphoma cells. International Journal of Cancer, 1991, 47, 544-550.	5.1	56
143	The epstein-barr-virus-encoded membrane protein LMP but not the nuclear antigen EBNA-1 induces rejection of transfected murine mammary carcinoma cells. International Journal of Cancer, 1991, 48, 794-800.	5.1	42
144	Search for the critical characteristics of phenotypically different B cell lines, Burkitt lymphoma cells and lymphoblastoid cell lines, which determine differences in their functional interaction with allogeneic lymphocytes. Cancer Immunology, Immunotherapy, 1991, 34, 128-132.	4.2	14

#	Article	lF	CITATIONS
145	Generation of T cell clones binding F(ab′)2 fragments of the idiotypic immunoglobulin in patients with monoclonal gammopathy. Cancer Immunology, Immunotherapy, 1991, 34, 157-162.	4.2	27
146	Expression of the Epstein-Barr virus (EBV)-encoded membrane antigen (LMP) increases the stimulatory capacity of EBV-negative B lymphoma lines in allogeneic mixed lymphocyte cultures. European Journal of Immunology, 1990, 20, 2293-2299.	2.9	41
147	Up regulation of the Epstein-Barr virus (EBV)-encoded membrane protein LMP in the Burkitt's lymphoma line Daudi after exposure to n-butyrate and after EBV superinfection. Journal of Virology, 1990, 64, 5441-5447.	3.4	35
148	Epstein-Barr virus (EBV) antigens processed and presented by B cells, B blasts, and macrophages trigger T-cell-mediated inhibition of EBV-induced B-cell transformation. Journal of Virology, 1990, 64, 1398-1401.	3.4	31
149	Reversion of tumorigenicity and decreased agarose clonability after EBV conversion of an igh/myc translocation-carrying be line. International Journal of Cancer, 1989, 43, 273-278.	5.1	30
150	Relationship between clinical stage, histopathology and antibody titers against the second epstein-barr virus nuclear antigen (EBNA-2) in non-Hodgkin's lymphoma patients. International Journal of Cancer, 1989, 43, 1017-1021.	5.1	5
151	5-Azacytidine up regulates the expression of Epstein-Barr virus nuclear antigen 2 (EBNA-2) through EBNA-6 and latent membrane protein in the Burkitt's lymphoma line rael. Journal of Virology, 1989, 63, 3135-3141.	3.4	153
152	Differential expression of hla antigen of HLA anigens on human Bâ€cell lines of normal and malignant origin: A consequence of immune surveillance or a phenotypic vestige of the progenitor cells?. International Journal of Cancer, 1988, 41, 913-919.	5.1	34
153	T-cell-mediated inhibition of EBV-induced B-cell transformation: Recognition of virus particles. International Journal of Cancer, 1988, 42, 359-364.	5.1	16
154	Expression of the Epstein-Barr virus encoded EBNA-I gene in stably transfected human and murine cell lines. International Journal of Cancer, 1988, 42, 592-598.	5.1	3
155	Combined treatment with interferon (IFN)-Î ³ and tumor necrosis factor (TNF)-α up-regulates the expression of HLA class I determinants in Burkitt lymphoma lines. Cellular Immunology, 1988, 117, 303-311.	3.0	15
156	Down-regulation of class I HLA antigens and of the Epstein-Barr virus-encoded latent membrane protein in Burkitt lymphoma lines Proceedings of the National Academy of Sciences of the United States of America, 1987, 84, 4567-4571.	7.1	133
157	Analysis of Epstein-Barr virus-specific and non-specific immune functions in a patient during the development of a non-Hodgkin's lymphoma. European Journal of Cancer & Clinical Oncology, 1987, 23, 379-386.	0.7	4
158	Characterization of ebv-carrying b-cell populations in healthy seropositive individuals with regard to density, release of transforming virus and spontaneous outgrowth. International Journal of Cancer, 1987, 39, 472-476.	5.1	100
159	Defective cell-mediated response to EBV-transformed B cells in a healthy individual with regular EBV antibody titers. International Journal of Cancer, 1987, 40, 149-156.	5.1	5
160	Down-regulation of the EBV-encoded membrane protein (LMP) in burkitt lymphomas. International Journal of Cancer, 1987, 40, 358-364.	5.1	35
161	Paired Epstein-Barr virus (EBV)-negative and EBV-converted Burkitt lymphoma lines: Stimulatory capacity in allogeneic mixed lymphocyte cultures. International Journal of Cancer, 1987, 40, 691-697.	5.1	45
162	Activation of B lymphocytes by Epstein-Barr virus/CR2 receptor interaction. European Journal of Immunology, 1987, 17, 815-820.	2.9	34

#	Article	IF	CITATIONS
163	Differentiation-dependent sensitivity of human B-cell-derived lines to major histocompatibility complex-restricted T-cell cytotoxicity Proceedings of the National Academy of Sciences of the United States of America, 1986, 83, 5620-5624.	7.1	97
164	B cell activation by the nontransforming P3HR-1 substrain of the Epstein-Barr virus (EBV). European Journal of Immunology, 1986, 16, 841-845.	2.9	17
165	Cytotoxic factor produced by human blood lymphocytes of low density upon exposure to autologous B cells. Immunology Letters, 1986, 12, 141-146.	2.5	1
166	Differential effect of cyclosporin-A on the mixed-lymphocyte culture-induced proliferative and cytotoxic responses of T lymphocytes with different cell densities. Cellular Immunology, 1986, 103, 409-416.	3.0	3
167	Differential recognition of tumor-derived and in vitro Epstein-Barr virus-transformed B-cell lines by fetal calf serum-specific T4-positive cytotoxic T-lymphocyte clones. Cellular Immunology, 1986, 98, 453-466.	3.0	16
168	Modulation of human blood lymphocyte cytotoxicity by the phorbol ester tumor promoter P(Bu)2: Increase of target binding, impairment of effector recycling, and activation of lytic potential which is independent of IL-2. Cellular Immunology, 1985, 91, 178-192.	3.0	8
169	Selective inhibitory effect of Hu-IFN-Î ³ on the agarose clonability of tumor-derived lymphoid cell lines. Cellular Immunology, 1985, 90, 65-73.	3.0	4
170	Leukocyte migration inhibitory factor production by activated lymphocytes representing immunological memory or virus-receptor interaction: Response of T cell subsets to Epstein-Barr virus nuclear antigen, response of B cells to UV in activated Epstein-Barr virus. Immunology Letters, 1985, 9, 267-273.	2.5	3
171	Effect of cyclosporin-A (CsA) on the ability of T lymphocyte subsets to inhibit the proliferation of autologous EBV-transformed B cells. International Journal of Cancer, 1985, 35, 327-333.	5.1	16
172	Production of leukocyte migration inhibitory factor (LIF) in human lymphocyte subsets exposed to polyclonal activators. Cellular Immunology, 1984, 85, 511-518.	3.0	11
173	Natural killer cell sensitivity of human lymphoid lines of B-cell origin does not correlate with tumorigenicity or with the expression of certain differentiation markers. Cellular Immunology, 1984, 86, 278-286.	3.0	12
174	Lysis of tumor biopsy cells by blood lymphocyte subsets of various densities. Autologous and allogeneic studies. International Journal of Cancer, 1984, 33, 185-192.	5.1	21
175	Virologic, immunologic, and clinical observations on a patient during the incubation, acute, and convalescent phases of infectious mononucleosis. Clinical Immunology and Immunopathology, 1984, 30, 437-450.	2.0	80
176	Large granular lymphocytes inhibit the in vitro growth of autologous Epstein-Barr virus-infected B cells. Cellular Immunology, 1983, 76, 311-321.	3.0	100
177	The Tumor Promoter Phorbol-12,13-Dibutyrate [P(BU)2] Stimulates Cytotoxic Activity of Human Blood Lymphocytes. Immunobiology, 1983, 165, 403-414.	1.9	13
178	Comparison of highly NK active human lymphocyte subsets separated by various procedures involving E, EA rosetting, density gradients and adherence to immune complexes. Journal of Immunological Methods, 1983, 63, 57-67.	1.4	11
179	Lysis of tumor biopsy cells by autologous T lymphocytes activated in mixed cultures and propagated with T cell growth factor Journal of Experimental Medicine, 1982, 155, 83-95.	8.5	80
180	Natural killer activity of human blood lymphocytes. Molecular Immunology, 1982, 19, 1323-1329.	2.2	13

#	Article	IF	CITATIONS
181	Human T Cell Growth Factor (TCGF) produced by repeated stimulation of non-adherent human lymphocytes. Journal of Immunological Methods, 1982, 51, 35-44.	1.4	10
182	Effect of different Epstein-Barr virus-determined antigens (EBNA, EA, and VCA) on the leukocyte migration of healthy donors and patients with infectious mononucleosis and certain immunodeficiencies. Clinical Immunology and Immunopathology, 1982, 22, 128-138.	2.0	31
183	Activation of human blood lymphocyte subsets for cytotoxic potential. Cellular Immunology, 1982, 69, 21-33.	3.0	14
184	Human blood lymphocyte subsets separated on the basis of nylon adherence, SRBC and EA rosetting: Natural cytotoxicity and characterization with monoclonal reagents. Cellular Immunology, 1982, 69, 166-174.	3.0	13
185	Use of cryopreserved lymphocytes for the indirect leukocyte migration inhibition assay. Journal of Immunological Methods, 1981, 46, 369-374.	1.4	11
186	Target selectivity of interferon-induced human killer lymphocytes related to their Fc receptor expression Proceedings of the National Academy of Sciences of the United States of America, 1980, 77, 3620-3624.	7.1	36
187	Interferon suppresses antigen- and mitogen-induced leukocyte migration inhibition. Nature, 1980, 288, 594-596.	27.8	24
188	Effect of interferon-alpha 1 from E. coli on some cell functions. Science, 1980, 209, 1431-1435.	12.6	89